Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations

2001 ◽  
Vol 20 (5) ◽  
pp. 197-204 ◽  
Author(s):  
Manolova I. ◽  
Dancheva M. ◽  
Halacheva K.
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antineutrophil Cytoplasmic Antibodies ◽  
Antigen Specificity ◽  
Systemic Lupus ◽  
Clinical Associations

Increased Serum Soluble OX40 in Patients with Systemic Sclerosis

2008 ◽  
Vol 35 (12) ◽  
pp. 2359-2362 ◽  
Author(s):  
KAZUHIRO KOMURA ◽  
AYUMI YOSHIZAKI ◽  
MASANARI KODERA ◽  
YOHEI IWATA ◽  
FUMIHIDE OGAWA ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Systemic Sclerosis ◽  
Lupus Erythematosus ◽  
Tumor Necrosis ◽  
Disease Duration ◽  
Tumor Necrosis Factor Receptor ◽  
Healthy Individuals ◽  
Systemic Lupus ◽  
Clinical Associations ◽  
Necrosis Factor

ObjectiveTo determine levels of serum soluble OX40 (also termed CD134, a member of the tumor necrosis factor receptor superfamily) and their clinical associations in patients with systemic sclerosis (SSc).MethodsSerum soluble OX40 levels were examined by ELISA in 53 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 32 healthy individuals.ResultsOX40 levels were significantly elevated in SSc patients (125.7 ± 5.7 pg/ml) compared to patients with SLE (80.7 ± 1.7 pg/ml; p < 0.005) and controls (88.2 ± 3.0 pg/ml; p < 0.0001). Elevated OX40 levels were found to be associated with disease duration of less than 2 years (p < 0.05).ConclusionOur results suggest that serum soluble OX40 levels correlate with the early-onset of SSc disease.

scholarly journals High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients

Lupus ◽  
2020 ◽  
Vol 29 (11) ◽  
pp. 1412-1422 ◽  
Author(s):  
Sahwa Elbagir ◽  
Amir I Elshafie ◽  
Elnour M Elagib ◽  
NasrEldeen A Mohammed ◽  
Mawahib IE Aledrissy ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
South African ◽  
Lupus Erythematosus ◽  
Fetal Loss ◽  
African Origin ◽  
Systemic Lupus ◽  
American College Of Rheumatology ◽  
Glycoprotein I ◽  
High Prevalence ◽  
Clinical Associations

Objectives IgA antiphospholipid antibodies (aPL) are prevalent in systemic lupus erythematosus (SLE) patients of African American, Afro-Caribbean and South African origin. Nevertheless, data from North Africa are lacking, and most studies use manufacturer-suggested cut-offs based on Caucasian controls. Therefore, we compared aPL isotypes in Sudanese and Swedish SLE patients using nation-based cut-offs. Methods Consecutive SLE patients and age- and sex-matched controls from Sudan ( N = 115/106) and Sweden ( N = 340/318) were included. All patients fulfilled the 1982 American College of Rheumatology SLE classification criteria. Antiphospholipid syndrome–related events were obtained from patients’ records. IgA/G/M anticardiolipin and anti-β2 glycoprotein I (β2GPI) were analysed with two independent assays. IgA anti-β2GPI domain 1 (D1) was also investigated. Manufacturers’ cut-offs and the 95th and 99th percentile cut-offs based on national controls were used. Results Sudanese patients and controls had higher levels and were more often positive for IgA aPL than Swedes when using manufacturers’ cut-offs. In contrast, using national cut-offs, the increase in IgA aPL among Sudanese patients was lost. Occurrence of IgA anti-D1 did not differ between the countries. Venous thromboses were less common among Sudanese patients and did not associate with aPL. No clinical associations were observed with IgA anti-β2GPI in Sudanese patients. Thromboses in Swedes were associated with IgG/M aPL. Fetal loss was associated with aPL in both cohorts. Conclusions IgA anti-β2GPI prevalence was higher among Sudanese compared to Swedish patients when manufacturers’ cut-offs were used. This situation was reversed when applying national cut-offs. Anti-D1 was not increased in Sudanese patients. Previous studies on populations of African origin, which demonstrate a high prevalence of IgA aPL positivity, should be re-evaluated using a similar cut-off approach.

The future of lupus therapy modulating autoantigen recognition

Lupus ◽  
2010 ◽  
Vol 19 (12) ◽  
pp. 1474-1481 ◽  
Author(s):  
A. Okamoto ◽  
K. Fujio ◽  
K. Yamamoto
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cells ◽  
Lupus Erythematosus ◽  
Current Treatment ◽  
Antigen Specificity ◽  
Therapeutic Approaches ◽  
Systemic Lupus ◽  
Serious Adverse Events ◽  
Promising Therapeutic Approach ◽  
Essential Components

The mainstay of the current treatment for systemic lupus erythematosus consists of steroids and immunosuppressants. However, these non-specific immunosuppressive therapies can cause infection and other serious adverse events. The regulation of the autoantigen-specific immune response is a promising therapeutic approach with maximal efficacy and minimal adverse effects. T cells are essential components of antigen-specificity in the immune system. At present, we do not have a sufficient strategy for manipulating the responses of antigen-specific T cells. In this review, we describe the efficacy of two therapeutic approaches involving the modulation of autoantigen recognition by T cells in lupus model mice: (1) therapy involving engineered autoantigen-specific regulatory T cells generated by the gene transfer of autoantigen-specific TCR genes and appropriate regulatory genes into self lymphocytes; (2) therapy involving selective depletion of autoantigen presenting phagocytes. These selective immunosuppressive approaches could be useful strategies for the treatment of systemic lupus erythematosus.

scholarly journals ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS

Rheumatology ◽  
1996 ◽  
Vol 35 (7) ◽  
pp. 625-631 ◽  
Author(s):  
P. E. SPRONK ◽  
H. BOOTSMA ◽  
G. HORST ◽  
M. G. HUITEMA ◽  
P. C. LIMBURG ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antineutrophil Cytoplasmic Antibodies ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document